Filing Flows › Comparisons › CBIO vs KRSA
Crescent Biopharma vs Korsana Biosciences: CBIO and KRSA compared
Crescent Biopharma is the larger company: $1.0M of revenue in its latest quarter (Q1 2026) against $1.0M for Korsana Biosciences (Q4 2025).
Where the money goes: CBIO and KRSA
Crescent Biopharma (CBIO) · Q1 2026
Crescent Biopharma, Q1 2026: revenue $1.0M, net loss $23.3M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Korsana Biosciences (KRSA) · Q4 2025
Korsana Biosciences, Q4 2025: revenue $1.0M (-43% year over year), operating margin -81.8%, net loss $799K, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
| Crescent Biopharma (CBIO) | Korsana Biosciences (KRSA) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q4 2025 |
| Revenue | $1.0M | $1.0M |
| Revenue growth, Y/Y | — | -43% |
| Operating margin | n/m | -81.8% |
| Net earnings | −$23.3M | −$799K |
| Net margin | — | -78.0% |
| Operating cash flow | −$8.9M | −$1.6M |
Questions
Which is bigger, Crescent Biopharma or Korsana Biosciences?
Crescent Biopharma is the larger company: $1.0M of revenue in its latest quarter (Q1 2026) against $1.0M for Korsana Biosciences (Q4 2025).
More: Crescent Biopharma earnings · how Crescent Biopharma makes money · Korsana Biosciences earnings · how Korsana Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Apr 29, 2026; 10-K filed Mar 30, 2026). Fiscal quarters can end on different dates. Not investment advice.